



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit go.covermymeds.com/OptumRx to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

Sandostatin[®], Sandostatin[®] LAR Depot & octreotide acetate Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand		Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy			

Clinical Information (required)

Select the diagnosis below:

Acromegaly

Carcinoid tumor requiring symptomatic treatment of severe diarrhea or flushing

Chemotherapy- and/or radiation-induced diarrhea

HIV/AIDS-related diarrhea

Vasoactive intestinal peptide tumor requiring symptomatic treatment of diarrhea

Other diagnosis: _____ ICD-10 Code(s): _____

Medication History:

For brand Sandostatin requests:
Has the patient had history of trial and failure, contraindication, or intolerance to generic octreotide acetate? Yes No

For Sandostatin LAR Depot requests:
Has the patient had a trial of short-acting octreotide and responded to and tolerated therapy? Yes No

For acromegaly, also answer the following:

Does the patient have acromegaly as confirmed by serum GH level greater than 1 ng/mL after a 2 hour oral glucose tolerance test (OGTT) or elevated serum IGF-1 levels (above age and gender adjusted normal range as provided by the physician's lab) at the time of diagnosis? Yes No

Has the patient had an **inadequate response or history of failure** to surgical resection and/or pituitary irradiation (radiotherapy) or is not a candidate for surgical resection or pituitary irradiation? Yes No

Has the patient had an **inadequate response or history of failure** to a dopamine agonist (e.g., bromocriptine, cabergoline)? Yes No

Does the patient have history of **intolerance** to dopamine agonist therapy at maximally tolerated doses? Yes No

Reauthorization:

Is there documentation the patient has had a positive clinical response to therapy (e.g., reduction or normalization of IGF-1/GH level for same age and sex, reduction in tumor size)? Yes No

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Sandostatin-SandostatinLARDepot-octreotideacetate_CMS_2019Jan-W



**Sandostatin[®], Sandostatin LAR Depot[®] & octreotide acetate
Prior Authorization Request Form (Page 2 of 2)**

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For carcinoid tumor requiring symptomatic treatment of severe diarrhea or flushing, also answer the following:

Does the patient have metastatic carcinoid tumor requiring symptomatic treatment of severe diarrhea or flushing episodes? Yes No

Is this request for continuation of therapy and the patient has used the requested medication within the past 120 days? Yes No

Reauthorization:

Is there documentation the patient has had a positive response while on therapy (improvement in the number of diarrhea or flushing episodes)? Yes No

For chemotherapy- and/or radiation-induced diarrhea, also answer the following:

Does the patient have **uncomplicated** diarrhea due to concurrent cancer chemotherapy and/or radiation? Yes No

Has the patient had trial and failure, contraindication, or intolerance to standard therapy (e.g., loperamide)? Yes No

Does the patient have **complicated** diarrhea due to concurrent cancer chemotherapy and/or radiation? Yes No

Reauthorization:

Is there documentation the patient has had a positive response while on therapy? Yes No

For HIV/AIDS-related diarrhea, also answer the following:

Has the patient had trial and failure, contraindication, or intolerance to standard therapy (e.g., loperamide, diphenoxylate with atropine)? Yes No

Reauthorization:

Is there documentation the patient has had a positive response while on therapy? Yes No

For vasoactive intestinal peptide tumor requiring symptomatic treatment of diarrhea, also answer the following:

Does the patient have vasoactive intestinal peptide tumor requiring treatment of profuse watery diarrhea? Yes No

Does the patient have metastatic disease? Yes No

Reauthorization:

Is there documentation the patient has had a positive response while on therapy (improvement in the number of diarrhea episodes)? Yes No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note:

This request may be denied unless all required information is received.

If the patient is not able to meet the above standard prior authorization requirements, please call 1-800-711-4555.

For urgent or expedited requests please call 1-800-711-4555.

This form may be used for non-urgent requests and faxed to 1-800-527-0531.